The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Medtronic; Medtronic; Medtronic; Medtronic
Research Funding - Abbott; Abbott; Abbott; Abbott; Cook Medical; Cook Medical; Cook Medical; Cook Medical
A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study.
 
Maarten C.C.M. Hulshof
No Relationships to Disclose
 
Debby Geijsen
No Relationships to Disclose
 
Tom Rozema
No Relationships to Disclose
 
Vera Oppedijk
No Relationships to Disclose
 
Jeroen Buijsen
No Relationships to Disclose
 
Karen J. Neelis
No Relationships to Disclose
 
Joost Nuyttens
No Relationships to Disclose
 
Maurice Van Der Sangen
No Relationships to Disclose
 
Paul Jeene
No Relationships to Disclose
 
Janny Reinders
No Relationships to Disclose
 
Mark I. van Berge Henegouwen
Consulting or Advisory Role - Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Medtronic (Inst); Medtronic (Inst); Medtronic (Inst); Medtronic (Inst); Mylan (Inst); Mylan (Inst); Mylan (Inst); Mylan (Inst)
Research Funding - Olympus (Inst); Olympus (Inst); Olympus (Inst); Olympus (Inst); Stryker (Inst); Stryker (Inst); Stryker (Inst); Stryker (Inst)
Travel, Accommodations, Expenses - Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
 
Jeanin E. van Hooft
No Relationships to Disclose
 
Hanneke W.M. Van Laarhoven
Honoraria - Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Nordic Group; Nordic Group; Nordic Group; Nordic Group; Servier; Servier; Servier; Servier
Research Funding - Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Nordic Group (Inst); Nordic Group (Inst); Nordic Group (Inst); Nordic Group (Inst); Philips Healthcare (Inst); Philips Healthcare (Inst); Philips Healthcare (Inst); Philips Healthcare (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Servier (Inst); Servier (Inst); Servier (Inst); Servier (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
 
Ate Van Der Gaast
No Relationships to Disclose